Dane C. Olevian

Dane C. Olevian

Auto-generated profile, based on publicly available information

Dane C. Olevian

West Virginia University Department of Pathology, Morgantown, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2024 in Cancer Gene Therapy
Verified
Journal Article
Open access
PDF file
MMMidhun Malla
Midhun Malla
SDSachin Kumar Deshmukh
Sachin Kumar Deshmukh
SWSharon Wu
Sharon Wu
TSTimothy Samec
Timothy Samec
DODane C. Olevian
Dane C. Olevian
LHLori Hazlehurst
Lori Hazlehurst
The expression of the protein Mesothelin (MSLN) is highly variable in several malignancies, including colorectal cancer (CRC), and high levels are associated with aggressive clinicopathological features and worse patient survival. Colorectal cancer is both a common and deadly cancer; being the third most common in incidence and second most common cause of cancer-related death. While systemic therapy remains the primary therapeutic option for most patients with stage IV (metastatic; m) CRC, their disease eventually becomes treatment refractory, and 85% succumb within 5 years. Microsatellite-stable (MSS) CRC tumors, which constitute more than 90% of patients with mCRC, are generally refractory to immunotherapeutic interventions. In our current work, we characterize MSLN levels in CRC, specifically correlating expression with clinical outcomes in relevant CRC subtypes, and explore how MSLN expression impacts the status of immune activation and suppression in the peritumoral microenvironment. Higher MSLN expression is prevalent in CMS1 and CMS4 CRC subtypes and correlates with higher gene mutation rates across the patient cohorts. Further, MSLN-high patients exhibit increased M1/M2 macrophage infiltration, PD-L1 staining, immune-inhibitory gene expression, enrichment in inflammatory, TGF-β, IL6/JAK/STAT3, IL2/STAT5 signaling pathways, and mutation in KRAS and FBXW7. Together, these results suggest that MSLN protein is a potential target for antigen-specific therapy and supports investigation into its tumorigenic effects to identify possible therapeutic interventions for patients with high MSLN expressing MSS CRC.

24 December 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
ABAhmed Bakhshwin
Ahmed Bakhshwin
LHLeal Herlitz
Leal Herlitz
SHShaomin Hu
Shaomin Hu
SRShahzad Raza
Shahzad Raza
DODane C. Olevian
Dane C. Olevian
MHMohamed I. El Hag
Mohamed I. El Hag
Immunotactoid deposition is a rare fibrillary deposition disease that is primarily seen in the kidney associated with paraproteinemia. Here, we report a case of hepatic immunotactoid deposition in a 67-year-old male with a history of smoldering myeloma and chronic kidney disease who underwent liver transplantation for metabolic dysfunction-related cirrhosis. Immunotactoid deposition was first identified in the explanted liver and recurred in the allograft within only seven weeks following transplantation, presenting as ascites with normal liver function tests. The patient's post-transplantation course was complicated by proteinuria and renal failure requiring dialysis. Histologic examination of both native and allograft liver demonstrated pink amorphous material occupying sinusoidal spaces that were Congo-red negative and IgM Kappa-restricted. Electron microscopy revealed characteristic deposits of electron-dense bundles of hollow microtubules with a 40 nm diameter within the sinusoids and space of Disse, consistent with immunotactoids. Therapy of the patient's underlying plasma-cell dyscrasia utilizing a Daratumumab-based regimen showed decreased serum paraproteins, resolution of ascites, and improved kidney function no longer requiring dialysis, without inducing rejection. The patient continues to respond to treatment 10 months post transplantation.